{"transactions":[{"id":775160,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-18T16:42:18.000Z","date":"2026-05-15","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.46,"value":24600.0,"ownership":{"direct":true},"balance_after":72510,"source":{"system":"sec-edgar","filing":"0001628280-26-035991","document":"wk-form4_1779136936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000162828026035991/wk-form4_1779136936.xml","form_type":"4"}},{"id":777146,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-15T20:39:20.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":56403,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":112653,"derivative":{"exercise_price":2.52,"expiration_date":"2036-05-13","underlying":"Common Stock","underlying_shares":56403},"source":{"system":"sec-edgar","filing":"0001628280-26-035665","document":"wk-form4_1778877558.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000162828026035665/wk-form4_1778877558.xml","form_type":"4"}},{"id":777145,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:39:20.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":24553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents grant of restricted stock units (the \"Retainer RSU Award\") payable solely in common stock of the Issuer. The Reporting Person elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the Retainer RSU Award shall vest quarterly in equal one-third installments through the remainder of 2026, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":62510,"source":{"system":"sec-edgar","filing":"0001628280-26-035665","document":"wk-form4_1778877558.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000162828026035665/wk-form4_1778877558.xml","form_type":"4"}},{"id":777144,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:39:20.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":28201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU award shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":37957,"source":{"system":"sec-edgar","filing":"0001628280-26-035665","document":"wk-form4_1778877558.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000162828026035665/wk-form4_1778877558.xml","form_type":"4"}},{"id":888202,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T21:08:23.000Z","date":"2026-02-23","kind":"purchase","planned":false,"acquired":true,"shares":9756,"price":4.1,"value":39999.6,"ownership":{"direct":true},"balance_after":9756,"source":{"system":"sec-edgar","filing":"0001628280-26-010605","document":"wk-form4_1771880900.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000162828026010605/wk-form4_1771880900.xml","form_type":"4"}},{"id":1100328,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-06-27T20:26:56.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":56250,"derivative":{"exercise_price":5.5,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001826667-25-000089","document":"wk-form4_1751056010.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000182666725000089/wk-form4_1751056010.xml","form_type":"4"}},{"id":1289637,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-01-31T23:05:15.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option shall fully vest on the one-year anniversary of the grant date of January 29, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":6250,"derivative":{"exercise_price":4.89,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001415889-25-002546","document":"form4-01312025_110111.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000141588925002546/form4-01312025_110111.xml","form_type":"4"}},{"id":1289636,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-01-31T23:05:15.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of January 29, 2025, subject to the Reporting Person's continued service with the Issuer on each respective vesting date."}],"balance_after":35000,"derivative":{"exercise_price":4.89,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-25-002546","document":"form4-01312025_110111.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000141588925002546/form4-01312025_110111.xml","form_type":"4"}},{"id":2048765,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-24T02:00:21.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":31950,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. (\"Ayala\"), Advaxis, Inc. (\"Advaxis\"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the \"Merger Agreement\"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the \"Ayala Common Stock\"), including restricted stock, was cancelled and converted into the right to receive 0.1874 shares (the \"Exchange Ratio\") of Advaxis common stock (the \"Advaxis Common Stock\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option vests or vested and becomes or became exercisable in sixteen substantially equal quarterly installments following the grant date, such that the option shall be fully vested on January 3, 2026."}],"balance_after":0,"derivative":{"exercise_price":9.105,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":31950},"source":{"system":"sec-edgar","filing":"0001213900-23-004542","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000121390023004542/ownership.xml","form_type":"4"}},{"id":2048764,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-24T02:00:21.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":19170,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. (\"Ayala\"), Advaxis, Inc. (\"Advaxis\"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the \"Merger Agreement\"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the \"Ayala Common Stock\"), including restricted stock, was cancelled and converted into the right to receive 0.1874 shares (the \"Exchange Ratio\") of Advaxis common stock (the \"Advaxis Common Stock\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option vests or vested and becomes or became exercisable in sixteen substantially equal quarterly installments following the grant date, such that the option shall be fully vested on January 4, 2025."}],"balance_after":0,"derivative":{"exercise_price":11.26,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":19170},"source":{"system":"sec-edgar","filing":"0001213900-23-004542","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000121390023004542/ownership.xml","form_type":"4"}},{"id":2048763,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-24T02:00:21.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":89000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. (\"Ayala\"), Advaxis, Inc. (\"Advaxis\"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the \"Merger Agreement\"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the \"Ayala Common Stock\"), including restricted stock, was cancelled and converted into the right to receive 0.1874 shares (the \"Exchange Ratio\") of Advaxis common stock (the \"Advaxis Common Stock\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each outstanding option to purchase Ayala Common Stock (each an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vests or vested and becomes or became exercisable as to 17,750 of the underlying shares of common stock on August 1, 2020 and as to the remainder of the shares in 12 equal quarterly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":5.16,"expiration_date":"2029-09-19","underlying":"Common Stock","underlying_shares":89000},"source":{"system":"sec-edgar","filing":"0001213900-23-004542","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000121390023004542/ownership.xml","form_type":"4"}},{"id":2048762,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-24T02:00:21.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":58520,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. (\"Ayala\"), Advaxis, Inc. (\"Advaxis\"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the \"Merger Agreement\"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the \"Ayala Common Stock\"), including restricted stock, was cancelled and converted into the right to receive 0.1874 shares (the \"Exchange Ratio\") of Advaxis common stock (the \"Advaxis Common Stock\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"All Ayala restricted stock awards that were outstanding immediately prior to the effective time of the merger were substituted and converted automatically into the right to receive a number of shares of restricted Advaxis Common Stock equal to the Exchange Ratio, subject to the terms and conditions applicable to the corresponding Ayala restricted stock awards. These shares consist of two grants of restricted stock which vest or vested as follows: (i) 8,520 shares granted on January 4, 2021 vesting quarterly over four years; and (ii) 50,000 shares granted on May 16, 2022 vesting quarterly over three years."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"All Ayala restricted stock awards that were outstanding immediately prior to the effective time of the merger were substituted and converted automatically into the right to receive a number of shares of restricted Advaxis Common Stock equal to the Exchange Ratio, subject to the terms and conditions applicable to the corresponding Ayala restricted stock awards. These shares consist of two grants of restricted stock which vest or vested as follows: (i) 8,520 shares granted on January 4, 2021 vesting quarterly over four years; and (ii) 50,000 shares granted on May 16, 2022 vesting quarterly over three years."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-23-004542","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000121390023004542/ownership.xml","form_type":"4"}},{"id":2270487,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-05-16T20:10:44.000Z","date":"2022-05-16","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted common stock, which will vest quarterly over a period of three years from May 16, 2022."}],"balance_after":58520,"source":{"system":"sec-edgar","filing":"0000899243-22-018134","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000089924322018134/doc4.xml","form_type":"4"}},{"id":2444359,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2022-01-05T21:05:54.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":31950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable  in sixteen substantially equal quarterly installments following the grant date, such that the option shall be fully vested on January 3, 2026."}],"balance_after":31950,"derivative":{"exercise_price":9.105,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":31950},"source":{"system":"sec-edgar","filing":"0000899243-22-000879","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000089924322000879/doc4.xml","form_type":"4"}},{"id":2829985,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2021-02-26T22:47:31.000Z","date":"2021-02-24","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vested and became exercisable as to 25% of the underlying shares of common stock on August 1, 2020 and will become vested and exercisable as to the remainder of the shares in 12 equal quarterly installments thereafter."}],"balance_after":89000,"derivative":{"exercise_price":5.16,"expiration_date":"2029-09-19","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000899243-21-008447","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000089924321008447/doc4.xml","form_type":"4"}},{"id":2829984,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-26T22:47:31.000Z","date":"2021-02-24","kind":"sale","acquired":false,"shares":3000,"price":17.4617,"value":52385.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":8520,"source":{"system":"sec-edgar","filing":"0000899243-21-008447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000089924321008447/doc4.xml","form_type":"4"}},{"id":2829983,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-26T22:47:31.000Z","date":"2021-02-24","kind":"exercise","acquired":true,"shares":3000,"price":5.16,"value":15480.0,"ownership":{"direct":true},"balance_after":11520,"source":{"system":"sec-edgar","filing":"0000899243-21-008447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000089924321008447/doc4.xml","form_type":"4"}},{"id":2899466,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2021-01-22T21:05:07.000Z","date":"2021-01-20","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vested and became exercisable as to 25% of the underlying shares of common stock on August 1, 2020 and will become vested and exercisable as to the remainder of the shares in 12 equal quarterly installments thereafter."}],"balance_after":92000,"derivative":{"exercise_price":5.16,"expiration_date":"2029-09-19","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000899243-21-002906","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000089924321002906/doc4.xml","form_type":"4"}},{"id":2899465,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-22T21:05:07.000Z","date":"2021-01-20","kind":"sale","acquired":false,"shares":3000,"price":15.0279,"value":45083.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":8520,"source":{"system":"sec-edgar","filing":"0000899243-21-002906","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000089924321002906/doc4.xml","form_type":"4"}},{"id":2899464,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-22T21:05:07.000Z","date":"2021-01-20","kind":"exercise","acquired":true,"shares":3000,"price":5.16,"value":15480.0,"ownership":{"direct":true},"balance_after":11520,"source":{"system":"sec-edgar","filing":"0000899243-21-002906","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000089924321002906/doc4.xml","form_type":"4"}},{"id":2916204,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2021-01-06T21:05:13.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":19170,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable  in sixteen substantially equal quarterly installments following the grant date, such that the option shall be fully vested on January 4, 2025."}],"balance_after":19170,"derivative":{"exercise_price":11.26,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":19170},"source":{"system":"sec-edgar","filing":"0000899243-21-000682","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000089924321000682/doc4.xml","form_type":"4"}},{"id":2916203,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":46473,"kind":"person","name":"Gordon Gary B.","position":1,"cik":"0001811354","reported_name":"Gordon Gary B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-06T21:05:13.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":8520,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8520,"source":{"system":"sec-edgar","filing":"0000899243-21-000682","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811354/000089924321000682/doc4.xml","form_type":"4"}}]}